Christian Flanery

Christian Flanery serves as a key procurement professional within the CDC Office of Acquisition Services, supporting the agency’s mission to safeguard public health through strategic acquisition of critical scientific and medical resources. He manages a diverse portfolio of contracts focused on laboratory diagnostics, biomedical research tools, and public health infrastructure, ensuring timely access to high-performance analytical instruments, reagents, and biotechnology solutions. His work directly enables CDC’s response to infectious disease threats by facilitating the procurement of mission-critical equipment and services that underpin national surveillance, testing capacity, and epidemiological research operations. Flanery maintains consistent partnerships with leading providers in the life sciences and public health sectors, including General Dynamics Information Technology, GlaxoSmithKline, MRIGLOBAL, and Cepheid. These relationships are built on long-term contract vehicles that support complex, high-stakes procurement needs such as next-generation sequencing platforms, rapid diagnostic test kits, and bioinformatics systems. His contracting approach emphasizes performance-based outcomes, technical compliance, and supply chain resilience, often leveraging Indefinite-Delivery, Indefinite-Quantity (IDIQ) and Other Transaction Authority (OTA) mechanisms to accelerate deployment during public health emergencies. Flanery’s procurement portfolio reflects a strong preference for full and open competition, with 100% of awards issued under no set-aside classifications. This underscores a strategic focus on maximizing technical capability and market competition rather than socioeconomic set-asides, prioritizing mission-critical performance over socioeconomic categorization in high-risk, time-sensitive acquisitions. His primary procurement focus lies in NAICS 423490 (professional equipment and supplies wholesale) and 334516 (analytical laboratory instrument manufacturing), reflecting deep expertise in procuring clinical diagnostics, PCR systems, biosafety equipment, and specialized reagents. He also actively supports research and development in biotechnology (NAICS 541714), ensuring CDC’s scientific teams have access to cutting-edge tools for pathogen characterization, vaccine development, and data-driven public health modeling.